We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Novo Nordisk Broadens Into Neuro Drugs With Prothena Purchase

Novo Nordisk Broadens Into Neuro Drugs With Prothena Purchase

July 14, 2021

Novo Nordisk is exploring beyond its well-paved diabetes track, acquiring its first investigational neurological compound, PRX004, from Prothena in a deal potentially worth up to $1.2 billion.

For an upfront payment of $100 million, Novo Nordisk purchased both the phase 2-ready antibody, intended to treat transthyretin amyloidosis (ATTR), and Prothena’s entire ATTR developmental program. Prothena will also be eligible for $1.2 billion in development and sales milestone payments.

ATTR is a rare, progressive, fatal disease characterized by extracellular amyloid deposits in the heart and peripheral nerve tissue. PRX004 targets abnormally folded transthyretin (TTR) proteins. Produced in the liver, TTR transports vitamin A and the thyroid hormone thyroxine. About 400,000 patients have wild-type ATTR and 50,000, the inherited form.

View today's stories

Pharmaceuticals Commercial Operations

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 14Sep

    Omnichannel Engagement: Are You Digitally Ready?

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Organogenesis Gets 510(k) Clearance to Expand PuraPly Portfolio

  • FDA Grants Priority Review to sNDA for Lynparza

  • Visibly Gets 510(k) Clearance for Its Online Eye Test

  • Resilience Inks Collaboration Deal With Mayo Clinic Over Biotherapeutics

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing